Postoperative analgesia and plasma concentrations ofbupivacaine were evaluated in six patients receiving intermittent epidural bupivacaine for a period of 72 hours following large bowel surgery. Repeated doses were administered every hour by a new automatic, specially designed pump. Venous plasma bupivacaine concentrations showed accumulation for up to 48-60 hours during administration and were mostly less than 2 Ilg/ml except in an elderly, frail patient in whom a peak of 3.9 Ilg/ml was observed. This convenient, low-dose, pulsed technique provided excellent analgesia although special care may be necessary in the elderly and frail patient if potentially toxic levels are to be avoided.
alarms) which administers accurately metered doses of bupivacaine at one-hourly intervals was used 3 (Neurotech Medical Services Pty. Ltd., P.O. Box 270, Balwyn, Victoria 3103, Australia).
As plasma concentrations of bupivacaine during prolonged CEA have not been previously described, we decided to investigate these intensively in a small group of patients. This study therefore sets out to assess the resulting plasma concentrations of bupivacaine when one-hourly top-up cycles are used for the first 72 hours of the postoperative period following major abdominal surgery.
PATIENTS AND METHODS Six patients (three male, three female) between the ages of 35 and 67 years, ASA categories 1 or 2, undergoing elective large bowel resection took part in the study ( Table  1 ). All patients were informed of the nature of the investigation during the preoperative visit, and consent was obtained. Bupivacaine hydrochloride with adrenaline 1 :200,000 (Astra Pharmaceuticals Pty. Ltd.) was used. 35  57  2-3  2  64  82  2-3  3  63  78  3  4  64  70  4  5  67  38  2  6 62 78 [3] [4] Insertion of the epidural catheter was performed at either TI0-ll or TII-12 interspace preoperatively and 10-15 ml bupivacaine 0.5% with adrenaline 1 :200,000 injected. Postoperatively topping-up was performed by a purpose-designed pump. 3 This commenced when the patient first complained of abdominal pain. Initially, a dose of 3 ml was administered as a bolus every 60 minutes at a rate of 2.5 ml per minute. Every 12 hours pain relief was assessed clinically and the dose altered accordingly, with the aim of providing total absence of abdominal pain.
Venous blood samples (for plasma bupivacaine estimations) were taken from an indwelling central venous catheter. Samples were taken at IO-minute intervals for 60 minutes every 12 hours for a total of 72 hours. Venous blood was also taken prior to surgery as a control. Loss of ability to extend the knee against gravity 3
Loss of ability to dorsiflex the foot o   No pain on coughing  I  Pain on coughing but not on deep breathing  2  Pain on deep breathing but not at rest  3 Some pain at rest but desires no other analgesia 4 = Pain at rest, desires more analgesia Extent of the block and pain scores were assessed at the same time as the venous samples were taken.
The spread and degree of nerve blockade were assessed by: (a) sensory -fine pin prick; (b) motor -four-point scale 4 (Table 2 ); (c) pain score -(i) visual linear analogue (VLA) scale following a deep breath;5 (ii) verbal descriptive scale 6 ( Table 3) . The blood samples were collected into plastic tubes containing lithium heparin and centrifuged to provide plasma. The plasma was stored at minus 20°C until analysis. Samples were collected at 0, 10, 20, 30, 40 and 60 minutes after the bupivacaine doses administered at 0, 1, 12, 24, 36, 48, 60 and 72 hours. The zero time sample was taken immediately before the administration of the bupivacaine dose. Bupivacaine concentrations were assayed in triplicate by gas liquid chromotography and the mean of these assays used. 7 ,8 To 1.0 ml plasma in a 10 ml glass centrifuge tube was added 50 III aqueous cyproheptadine hydrochloride solution (lOO Ilg/ml), 0.2 ml sodium hydroxide solution (7 M) and 5 ml ether (Chrom AR, Mallinckrodt). The mixture was vortex mixed for two minutes and centrifuged. The ether layer was transferred to a clean, dry glass tube with a tapered base, evaporated to dryness under a stream of nit~o~en and reconstituted with 200 III redIstIlled ethyl acetate (AR grade, Ajax Chemicals). Two microlitres of this solution was then injected into a Perkin Elmer Sigma 3B <!~s Chromatograph filled with a nitrogen senSItIve detector.
The column was glass, 2 m X 2 mm ID packed with 2.5% QV-I7 on Chromosorb WHP, 100-120 (S.G.E., Melbourne, Australia). The column injector and detector temperatures were 250°, 300° and 300°C respectively, the carrier gas nitrogen flow rate was 30 mllmin and the bead current was 4.2 mA. Under these conditions the retention times for bupivacaine and cyproheptadine were 2.9 and 4.1 min respectively.
The meal!.. plasma bupivacaine concentration (C) during each one hour blood sampling period was calculated as C = Anaesthesia and Intensive Care. Vol. 15 . No. 4. November. 1987 AUC/T where AUC is the area under the graph of plasma concentration versus time (calculated by trapezoidal rule) and T is the duration of the sampling period (1 hour). 9 Premedication was with papavaretum 10 mg and hyoscine 0.2 mg for females and 15 mg and 0.3 mg for males respectively. Patients were given a light general anaesthetic during the operation in addition to epidural anaesthesia. Pethidine 25 mg intravenously was ordered to be given by the nursing stafffor sedation or analgesia as required. The nursing staff were present during top-up in order to monitor the pump's function. Pulse rate and blood pressure recordings were performed every hour at this time and repeated 1 5 minutes later. Ephedrine 30 mg intramuscularly was ordered when the systolic blood pressure fell below 90 mmHg. Urine output and central venous pressure were measured every hour.
RESULTS
The plasma bupivacaine concentration versus time profile during each 60-minute estimation period is shown for patient 4, which is representative of those for other patients (Figure 1 ). Variation in the plasma concentration between the six samples collected during individual one-hour intervals was small and there was no overall pattern in each individual profile, e.g. with respect to the time of maximum or minimum plasma concentration. Bupivacaine accumulated in plasma with successive doses for up to 60 hours. In four of the patients (2, 4, 5, 6) mean concentrations declined somewhat after the maximum was reached. Figure 2 shows the profiles of the mean plasma bupivacaine cOl!fentration for each 60-minute estimation (C) for all six patients. Bupivacaine accumulated in the plasma of all patients and maximum mean plasma concentrations were reached by 48-60 hours.
The maximum individual concentration recorded was 3.91 Ilglml which occurred at 72 hours in patient 5. The mean peak plasma bupivacaine concentration in the study was 1.89 (SO 1.46) Ilglml. The individual peak concentrations and the times they were reached are shown in Table 4 . No signs of clinical toxicity attributable to bupivacaine were noted in any patient during the course of the study. Table 5 contains the analgesia and motor block profiles of all six patients. Excellent relief of abdominal pain was achieved in all patients as shown by a VLA score above 75.
Three patients received one dose of pethidine and one patient (number 3) three doses. However, in these cases it was administered by the nursing staff to cover areas of discomfort other than the abdomen, experienced colicky abdominal pain due to contractions of the gut. Two patients received pethidine for this although it was found to be ineffective. Hyoscine-N -bu tylbromide (Buscopan) 10-20 mg was used instead with good effect. Three patients required a single dose of ephedrine and one (patient 6) two doses for blood pressure falls below 90 mmHg systolic. Severe hypotension (systolic BP less than 80 mmHg) did not occur. Mild to moderate systolic hypotension (85-100 mmHg) tended to occur during the first 24 hours. As hypotension was invariably accompanied by a fall in the hourly urine output to below 50 ml/hr and low central venous pressure, the preferred method of treatment was to increase Tachyphylaxis did not occur and the upper and lower limits of sensory block remained constant. Motor block of the lower limbs was insignificant, enabling assisted ambulation ( Table 5) . DISCUSSION A major concern with the repeated administration of local anaesthetics is the possibility of toxicity due to the accumulation of the drug in the systemic circulation. 10 .1 I The extent of accumulation of a drug increases with the ratio elimination half-life/dosage interva1. 9 After epidural administration, the elimination of local anaesthetic from plasma is rate-limited by the rate of absorption. 12 For epidural bupivacaine the elimination half-life is approximately nine hours: 13 therefore hourly epidural doses of bupivacaine would be expected to result in substantially higher steady-state plasma concentrations compared with those achieved after the first dose. This is evident in Figure 2 . Apart from patient 5, higher steady-state plasma concentrations were associated with higher bupivacaine dosage. The plasma concentrations reached in patient 5, who was aged 67 years and weighed 38 kg, suggests that caution should be exercised when treating such patients. The time taken to achieve steady-state was 48-60 hours (Figure 2 ) which is consistent with kinetic principles which predict that steadystate should be reached within 5-7 drug elimination half-lives. A similar accumulation profile has been observed with continuous epidural administration of lignocaine. 14 Absorption of bupivacaiile into the systemic circulation was extremely rapid after each hourly dose as evidenced by the very rapid rise and early peaking of the plasma bupivacaine concentration (Figure 1 ). This is consistent with the notion put forward that systemic absorption from the epidural space can be viewed as an initial rapid phase followed by a much slower and more prolonged phase. II Peak concentrations were reached in most cases within 10 minutes of injection however, which signifies a much more rapid initial absorption phase than observed in previous studies. II • 15 The reason Anaesthesia and Intensive Care, VD!. 15, No. 4, November, 1987 for this difference is not known. Overall, the fluctuation in plasma bupivacaine concentrations between consecutive doses was small (Figure 1) .
The decrease in mean plasma bupivacaine concentrations in four of the patients after the maximum had been reached was surprising and is due either to an increase in plasma clearance of bupivacaine or a decrease in absorption rate (Figure 1 ). There is no information available on clearance changes during continuous bupivacaine administration. A study of the related compound, lignocaine, administered intravenously, showed a 35% decrease in clearance after 24 hours continuous administration. 16 This indicates that decreased absorption is the probable mechanism rather than an increased clearance.
Various estimates of the maximum safe plasma concentration of bupivacaine have been proposed but there is general agreement that an arterial concentration below 4 Ilglml is safe. 15 ,17.18 It has been shown that arterial plasma concentrations of 5.1-5.4 Ilglml of bupivacaine are required to cause convulsions. 18 In all but patient 5, venous concentrations were well below this threshold, demonstrating that continuous pain relief can be obtained with this technique without exposing patients to unduly high systemic concentrations of the drug. The venous plasma levels achieved in this study are comparable with arterial plasma levels obtained in another studylo allowing for the 20-40% higher peak arterial concentrations over venousY No toxicity due to absorption of bupivacaine was observed in the present study.
Many papers have demonstrated the benefits and superior analgesia of epidural analgesia using local anaesthetic drugs for the relief of postoperative pain. 19 Unfortunately the combined disadvantages of short duration of action ofbupivacaine 21 • 22 and troublesome, possily dangerous complications such as severe hypotension and lower limb weakness, have severely limited its general use and acceptance. 10 Continuous infusion techniques have been tried to overcome these disadvantages, but results have proved disappointing compared with intermittent techniques. 2 . 1o ,23.24 In the present study using low-dose pulsed intermittent administration, serious complications attributable to epidural bupivacaine were not encountered.
Doses of bupivacaine were administered every hour, maintaining constant levels of analgesia without tachyphylaxis ( Table 5 ). Variations of more than one spinal segment between 12-hourly estimations occurred in only one patient. Excellent smooth and continuous relief from pain at rest and during deep breathing without sedation was the result. Relief from pain at rest is relatively easily achieved by other methods; however, this may not be so during deep breathing and coughing.
